Singapore
Wants You!
An offer bioscientists can't refuse: unrestricted
research, top-notch equipment, limitless funds. (Just leave
your chewing gum at home.) By Stuart Luman, Wired.com
Jul 29, 2004
Eight
years ago, Alan Colman and his team
of geneticists stunned the world when they cloned a sheep.
Dolly became a household name, and Colman found himself
in the spotlight.
He made appearances on NBC, CNN, and the BBC, and landed
more than a hundred invitations to lecture in front of audiences
around the globe: Islamic scholars in Dubai, philosophers
at Oxford University, biotech conferences in Delhi and Bangalore.
Suddenly Colman, who was working in Edinburgh, had his pick
of prestigious academic posts and private research labs
across the Western world. He turned them all down.
Instead,
he packed up his life and moved to the Southeast Asian city-state
of Singapore, where he is now sitting, explaining his next
big project over a tuna sandwich.
The 55-year-old scientist hopes to create insulin-producing
stem cells, which he'll use to treat diabetics, freeing
tens of millions of people from a lifetime of needles and
glucose monitoring.
Before Colman came to Singapore in 2002, his plan was just
a lofty goal in need of funding. Then Singapore dangled
a US$6 million grant if he'd agree to relocate.
"I met with venture capitalists in the US and the UK
and realised that it would be very difficult to fund the
work I wanted to do," he explains.
"But Singapore was prepared to put money into it. They're
not just interested in conventional returns on investment;
they're taking a long-term view. It really wasn't a difficult
decision."
Colman's
not alone. Singapore is treating hundreds of scientists
like free agents, promising first-class laboratories, top-notch
equipment, and more than enough money to pursue work that's
not fundable, or is too controversial, back home.
The government is investing more than US$2 billion into
research of all stripes, hoping to attract leaders in therapeutic
cloning, drug discovery, cancer research, and other areas,
bioscience all-stars who will in turn help build a local
community that will bolster the economy.
So far,
it's working.
A third of the almost 4,000 science PhDs here are foreigners,
many with impressive résumés. Edison Liu,
former director of the US National Cancer Institute's Division
of Clinical Sciences, moved in 2001 to head the Genome Institute
of Singapore.
Japanese cancer researcher Yoshiaki Ito brought his entire
Kyoto University team to Singapore's Institute of Molecular
and Cell Biology in 2002.
Nobel Prize-winning molecular biologist Sydney Brenner splits
his time between the Salk Institute for Biological Studies
in San Diego and advising Singapore on how to attract more
people like him.
The
government has also been successful in luring multinational
pharmaceutical companies.
Together, Singapore and Swiss pharmco Novartis founded the
Novartis Institute for Tropical Diseases.
With a 10-year, $120 million budget, scientists at the centre
will work to rid the developing world of scourges like tuberculosis
and dengue fever, a tropical disease that infects 50 million
annually.
TB kills nearly 2 million every year, mostly in poor regions.
Neither disease has received much attention from drug companies.
The government is working with Novartis to change all that.
Exhibit
A in Singapore's quest is Biopolis, a $300 million, 2 million-square-foot
complex taking shape just outside of downtown.
When complete by year's end, Biopolis will include institutes
specializing in bioinformatics, genomics, molecular biology,
and nanotech - not to mention a shopping mall, a fitness
center, restaurants, a day care centre, lecture halls, a
pub, and a light-rail system.
The gleaming food court features local delicacies like chicken
rice and laksa soup, Indian fried bread, a Malay beef dish
called rendang - and Wi-Fi. The main lobby is set off with
white Mies van der Rohe Barcelona chairs and an Achille
Castiglioni floor lamp.
But
it isn't the food or the furniture that lured Martin Hibberd
from his tenured post at London's Imperial College to run
the population genetics lab at the Genome Institute. It's
the equipment.
Biopolis labs are lavishly outfitted with mass spectrometers,
robotic microarrays, and a computing room that can house
a petabyte of data storage. On a tour of his facilities,
Hibberd proudly notes the $600,000 sequence variation analyzer
purchased by the government. The system can sequence 4,000
DNA samples a day. Then there are the four $400,000 Applied
Biosystems DNA analyzers. "At Imperial, it was hard
to get funding for new technology, but here it's available,"
he says. "We've gone from nothing to this in only a
short period of time."
Of course,
there are trade-offs for scientists who choose to live and
work in Singapore - a country that treats chewing gum like
contraband, canes graffiti artists, and executes drug dealers.
Such top-down control extends to the scientific community.
In exchange for funding, researchers effectively become
on-call consultants, expected to help on various problems
of the day in tandem with local scientists.
Colman spends 20 percent of his time doing government-sponsored
work and recruiting scientists.
During the 2003 SARS outbreak, Hibberd's boss asked him
to sequence the virus. He developed a diagnostic test, now
sold by Roche Pharmaceuticals, and will split royalties
with Roche and the government.
"In the UK, an academic institution would look down
on that," Hibberd says. "Here, I'm totally open."
By working
in the biotech community, foreign scientists will train
an emerging generation of Singaporean researchers, who will
one day rule Biopolis.
At least that's the plan. Getting to that point requires
an overhaul of the educational system, which has always
been based on rote memorisation and absolute respect for
authority.
For many countries, this would take forever, but things
happen more quickly here.
"Singapore works as a company," says Denmark-born
Søren Bested, CTO of CordLife, which banks stem cells
from the blood of umbilical cords.
"When a decision is made to support life sciences,
the government can provide billions in funding, build 2
million square feet of life science space in the middle
of town, and change the curriculum of all schools to incorporate
it."
The
bigger obstacle may be cultural. The government is suddenly
encouraging a type of creativity that it has all but purged
from this hermetically sealed country.
"People have had a very good deal here, but unfortunately
compliance is part of the problem for the future. They don't
think for themselves," says Colman. "This runs
through to science."
The
man responsible for setting Singapore's economic course:
Philip Yeo, cochair of the Singapore Economic Development
Board.
Having watched electronics manufacturing and financial services
flee to China and Taiwan, Yeo sees biotechnology as a way
to keep the city-state's economy afloat.
"If the whole world market for electronics or chemicals
shrinks, oops, we're in trouble," he says. "Biotech
is one more weapon."
It's an expensive gamble. By one estimate, US$60 billion
worldwide has been lost in private biotech investment since
1990.
Yeo doesn't seem worried. Officially, the country has US$100
billion in cash reserves. Unofficially, the number is much
higher, perhaps double. "Money is not a problem,"
he says. "My problem is people."
In his
search for world-class microbiologists, chemists, geneticists,
and the like, Yeo has given his pitch hundreds of times.
Yet he still gets excited about the change he's inciting.
He jumps up from the table in a Biopolis conference room
and starts writing on the frosted glass walls.
Biopolis, he explains, will be a creative environment where
Western scientists and an emerging class of Singaporean
researchers will work side by side.
"Anyone can build a building. But to do this"
- he points to his scribbles describing a massive scholarship
program - "the selection, the marketing to the kids,
that's our competitive edge. I'm looking for future leaders."
After
an hour, Yeo has covered nearly every inch of the glass
drawing board in charts, pyramids, and Venn diagrams. He
admires his handiwork and turns back to me. "This is
the only place you can graffiti," he says with a laugh.
"Elsewhere you go to jail!"
Wired.com